Local brain therapies associated with reduced mortality in HNSCC patients with brain metastasis
Local brain treatments linked to modest survival gains in rare head and neck cancer cases
This retrospective cohort analysis evaluated 201 patients with head and neck squamous cell carcinoma and brain metastasis from three tertiar…
Local brain treatments linked to lower death risk for rare head and neck cancer patients who develop brain metastases, though most still die…
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
20-fraction hypofractionated radiotherapy passes noninferiority for tumor control and late toxicity in locally advanced head and neck cancer
Shorter radiation schedule works as well for head and neck cancer
This randomized, open-label, Phase 3 noninferiority trial enrolled 792 patients with locally advanced head and neck squamous cell carcinoma …
A shorter radiation plan for head and neck cancer showed the same effectiveness as a longer schedule while reducing late side effects.
Systematic review and meta-analysis on immunotherapy for head and neck squamous cell carcinoma
Immunotherapy helps advanced head and neck cancer patients live longer
This systematic review and meta-analysis synthesized evidence on immunotherapy for head and neck squamous cell carcinoma. The authors report…
New analysis shows immune therapy helps advanced head and neck cancer patients survive longer when combined with other treatments
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Meta-analysis finds BCI_net prognostic for overall survival in oral squamous cell carcinoma
A new cancer test reads tumor cell chats to predict survival
This meta-analysis of 2 cohorts (TCGA-HNSC n=519, GSE65858 n=270) found that the BCI_net directional composite was independently associated …
Your cancer cells may be chatting with each other, and a new test that listens to those conversations could predict how aggressive the disea…
Narrative review on therapeutic cancer vaccines for head and neck squamous cell carcinoma
Review discusses cancer vaccines for head and neck cancer
This narrative review synthesizes evidence on therapeutic cancer vaccines, including personalized vaccines, for head and neck squamous cell …
This review looks at how cancer vaccines might work alongside other treatments for head and neck squamous cell carcinoma.
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Narrative review discusses HPV-associated head and neck and cervical squamous cell carcinoma without reporting specific outcomes
Doctors Find Hidden Pattern in HPV Cancers That Changes Treatment
This narrative review addresses patients with HPV-associated tumors involving head and neck squamous cell carcinoma and squamous cell carcin…
HPV cancers in the head and neck hide from the immune system differently than cervical cancers, explaining why some patients respond better …
Review of PBMC processing conditions in head and neck squamous cell carcinoma treatment-naive patients
New blood test method avoids risky biopsies for cancer patients
This observational study review examines peripheral blood mononuclear cell (PBMC) processing conditions for treatment-naive patients with he…
A new blood processing method lets doctors track immune health without risky biopsies for head and neck cancer patients.
Becotatug vedotin shows 20.9% objective response in recurrent head and neck squamous cell carcinoma after prior therapy
For patients with advanced head and neck cancer, a new drug showed a 21% response rate in early testing
This multicenter, Phase IIa trial evaluated intravenous becotatug vedotin in 67 patients with recurrent or metastatic squamous cell carcinom…
A new drug shrank tumors in 21% of patients with advanced head and neck cancer who had run out of standard treatment options.
Radiotherapy de-escalation strategies show reduced toxicity but modest clinical benefits in head and neck cancer cohorts
Smarter Radiation for Head and Neck Cancer May Spare Patients Misery
This narrative review examines radiotherapy de-escalation strategies for head and neck squamous cell carcinoma and HPV-related oropharyngeal…
Doctors are testing gentler radiation plans that protect quality of life for people with throat, mouth, and neck cancers facing harsh side e…
Research across Head and Neck Cancer
Related studies from across the Head and Neck Cancer family.
Advanced experimental models and computational tools provide dynamic frameworks for understanding oral disease progression
New Research Tools Help Map Complex Oral Diseases
This mini-review examines the integration of advanced experimental models, such as organ-on-chip systems and patient-derived organoids, with…
Advanced modeling and AI tools are helping researchers better understand the molecular causes behind conditions like gum disease and oral ca…
Microbial metabolites may promote or suppress cancer progression through inflammation, DNA damage, or immune modulation
Microbial metabolites may drive cancer growth or stop it through inflammation and DNA damage
This narrative review examines the role of microbial metabolites in carcinogenesis and cancer progression across multiple malignancies. The …
Microbial metabolites can promote cancer growth via inflammation or suppress it through immune changes, but we need more proof before using …
Molecular markers may improve risk assessment in oral potentially malignant disorders
Molecular tools may improve risk assessment for oral lesions
This narrative review examines the limitations of conventional histopathological grading for oral potentially malignant disorders (OPMDs) an…
A review suggests molecular methods could better assess risk for oral potentially malignant disorders where standard grading is unreliable.
Aspiration pneumonia affects 74.8% of head and neck cancer patients after chemoradiotherapy
Aspiration pneumonia strikes most head and neck cancer patients after chemoradiation
This supplementary analysis of a phase II/III trial in Japan found that 74.8% of 151 patients with resected high-risk head and neck cancer d…
Three in four head and neck cancer patients develop aspiration pneumonia after chemoradiation. Severe swallowing problems and reconstruction…
Radiotherapy and chemotherapy show no clear link to obstructive sleep apnea in head and neck cancer patients
Radiation for head and neck cancer may raise sleep apnea risk
This scoping review with exploratory meta-analysis of 13 studies found no significant association between radiotherapy or chemotherapy and i…
A review of 13 studies suggests a possible link between radiation for head and neck cancer and mild sleep apnea, but the evidence is too wea…
Robot-assisted oesophagectomy shows non-inferior survival in oesophageal squamous cell carcinoma
Robot-assisted surgery may improve survival for oesophageal cancer patients
A randomised trial compared robot-assisted versus thoracoscopic oesophagectomy for resectable oesophageal squamous cell carcinoma. The autho…
A large trial found robot-assisted oesophagectomy linked to higher five-year survival than thoracoscopic surgery for oesophageal squamous ce…
Scoping review of AI for head and neck cancer risk stratification
AI techniques show promise for staging head and neck cancer
This scoping review synthesized 44 studies on AI techniques for risk stratification in head and neck cancer. The authors found moderate to h…
A review of 44 studies suggests artificial intelligence could help predict cancer spread in head and neck cases, though more testing is need…
Narrative review covers diagnostic and treatment strategies for metastatic head and neck cancer with no identifiable primary tumor
Doctors use many tools to treat head and neck cancer when the main tumor is hidden
This narrative review addresses diagnostic and treatment strategies for metastatic cases of head and neck cancer with no identifiable primar…
When head and neck cancer spreads but the original spot is missing, doctors use many tools. Imaging, special tests, and surgery help find th…
Evidence mapping review on nutritional prehabilitation for head and neck cancer patients
Nutritional prehabilitation improves outcomes for head and neck cancer patients
This evidence mapping review synthesized 6 systematic evaluations, 13 randomized controlled trials, and 4 observational studies on pretreatm…
Nutritional prehabilitation helps patients with head and neck cancer by improving their nutritional status and quality of life while reducin…
Systematic review and meta-analysis of ML with cfDNA for cancer detection across stages
Simple blood test spots early cancer without scary scans
This systematic review and meta-analysis of 109 articles synthesized diagnostic performance of machine learning with circulating cell-free D…
• AI analyzes blood fragments to catch hidden cancers early • Helps people avoid painful biopsies and late diagnoses • Still in labs not rea…
Meta-analysis finds sex-based differences in ICI survival benefit for advanced gastroesophageal cancer
Immunotherapy Works Differently for Men and Women with Stomach Cancer
This meta-analysis of 15 RCTs examined immune-checkpoint inhibition for advanced gastroesophageal cancer. It found a significant overall sur…
Men with esophageal cancer gain a clear survival edge from immunotherapy, while women do not, but both sexes benefit similarly in stomach ca…
Narrative review explores mitochondrial-targeted therapeutics for oral squamous cell carcinoma
New drug strategy targets mouth cancer's hidden power source
This narrative review discusses the potential of mitochondrial-targeted therapeutics in oral squamous cell carcinoma (OSCC). The authors syn…
Targeting the cell's power source could help overcome stubborn mouth cancer resistance.
Questions about Head and Neck Squamous Cell Carcinoma
What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?
Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Full answer →Does reducing radiotherapy doses lower toxicity in head and neck squamous cell carcinoma?
Yes, reducing radiotherapy doses through margin reduction, adaptive planning, or proton therapy can lower acute and late toxicity in head and neck squamous cell carcinoma, though clinical benefits may be modest in unselected patients.
Full answer →What are the risks of HPV-associated head and neck squamous cell carcinoma?
HPV-associated head and neck squamous cell carcinoma risks include persistent HPV infection (especially HPV16), distinct metabolic changes, and epigenetic dysregulation, but these tumors often have a better prognosis than HPV-negative cancers.
Full answer →How do therapeutic cancer vaccines work for head and neck squamous cell carcinoma?
Therapeutic cancer vaccines train the immune system to recognize and attack HNSCC cells by targeting tumor-specific antigens, but achieving durable responses remains challenging.
Full answer →All Head and Neck Squamous Cell Carcinoma Articles
- Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
- Local brain therapies associated with reduced mortality in HNSCC patients with brain metastasis
- 20-fraction hypofractionated radiotherapy passes noninferiority for tumor control and late toxicity in locally advanced head and neck cancer
- Systematic review and meta-analysis on immunotherapy for head and neck squamous cell carcinoma
- FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
- Meta-analysis finds BCI_net prognostic for overall survival in oral squamous cell carcinoma
- Narrative review on therapeutic cancer vaccines for head and neck squamous cell carcinoma
- Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
- Narrative review discusses HPV-associated head and neck and cervical squamous cell carcinoma without reporting specific outcomes
- Review of PBMC processing conditions in head and neck squamous cell carcinoma treatment-naive patients
- Becotatug vedotin shows 20.9% objective response in recurrent head and neck squamous cell carcinoma after prior therapy
- Radiotherapy de-escalation strategies show reduced toxicity but modest clinical benefits in head and neck cancer cohorts
- Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
- Breg-related gene signature predicts survival and immune landscape in head and neck squamous cell carcinoma
- Regional motif diversity score in cfDNA predicts pembrolizumab response in head and neck cancer